Leveraging innate cell engagers for lymphoma treatment
European Pharmaceutical Review
DECEMBER 28, 2023
We received encouraging feedback from the US Food and Drug Administration (FDA) on the trial design and potential for accelerated approval. We also believe that bispecifics will further establish themselves as an important drug class in the treatment regimens for both haematological malignancies and solid tumours.
Let's personalize your content